Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells $1,281,645.72 in Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insider Bilal Arif sold 7,859 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Sarepta Therapeutics Trading Up 0.7 %

NASDAQ:SRPT opened at $157.96 on Friday. The company has a market cap of $14.93 billion, a P/E ratio of 1,436.00 and a beta of 0.96. The stock’s fifty day moving average price is $128.90 and its two-hundred day moving average price is $121.71. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The company had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. During the same quarter last year, the business posted ($1.44) earnings per share. The firm’s revenue was up 63.1% compared to the same quarter last year. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 3.71 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC raised its position in shares of Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after buying an additional 87 shares in the last quarter. Vanguard Capital Wealth Advisors raised its position in shares of Sarepta Therapeutics by 3.8% in the fourth quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after buying an additional 90 shares in the last quarter. Riggs Asset Managment Co. Inc. raised its position in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares in the last quarter. WCM Investment Management LLC raised its position in Sarepta Therapeutics by 2.3% during the first quarter. WCM Investment Management LLC now owns 6,279 shares of the biotechnology company’s stock valued at $813,000 after purchasing an additional 142 shares in the last quarter. Finally, Cary Street Partners Investment Advisory LLC raised its position in Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SRPT. Mizuho upped their target price on Sarepta Therapeutics from $145.00 to $179.00 and gave the company a “buy” rating in a report on Friday, May 17th. BMO Capital Markets upped their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday. UBS Group upped their target price on Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a report on Friday, March 1st. Oppenheimer raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $180.00 target price for the company in a report on Tuesday, May 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $235.00 target price on shares of Sarepta Therapeutics in a report on Thursday. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $185.06.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.